Friday, March 13, 2026 8:02:17 PM
I found an interview yesterday in which two of the authors laid out a three-pillar engineering roadmap to turn INSTALL from a proof-of-concept into something clinically usable.
A primary focus will be identifying LNP formulations capable of efficiently co-delivering recombinase mRNA and INSTALL. Concurrently, refining the chemical modifications and sequence composition of the PIP oligo. Furthermore, continued engineering of recombinases. With multiplicative gains across all three areas that should bring efficiency into clinically relevant territory.
A primary focus will be identifying LNP formulations capable of efficiently co-delivering recombinase mRNA and INSTALL. Concurrently, refining the chemical modifications and sequence composition of the PIP oligo. Furthermore, continued engineering of recombinases. With multiplicative gains across all three areas that should bring efficiency into clinically relevant territory.
Recent SGMO News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/06/2026 11:08:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:15:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:15:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:15:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:15:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:15:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/30/2026 09:29:20 PM
- Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results • GlobeNewswire Inc. • 03/30/2026 08:01:00 PM
- Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call • GlobeNewswire Inc. • 03/19/2026 08:03:00 PM
- Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease • GlobeNewswire Inc. • 03/09/2026 12:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 02:40:15 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/04/2026 01:35:30 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/04/2026 01:31:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/03/2026 09:07:22 PM
- Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026 • GlobeNewswire Inc. • 02/03/2026 09:05:00 PM
- Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering • GlobeNewswire Inc. • 02/03/2026 02:10:43 PM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 02/03/2026 02:07:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/03/2026 01:55:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2026 09:14:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2026 09:13:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2026 09:12:07 PM
